Teva- Pharmaceutical Industries Ltd
NYSE: TEVA
$17.50
+$0.07 (+0.4%)
Closing Price on November 7, 2024
TEVA Articles
Cowen asked the analysts which stocks should be on their shopping lists. Here are the six with the biggest upside potential.
Published:
These are the top analyst upgrades, downgrades and initiations from Wall Street firms for Wednesday, July 23, 2014. They include DuPont, General Electric, King, Microsoft, Xilinx and McDonald's.
Published:
In a recent research report, UBS specifically mentions six companies that it advises investors not to use an option strategy on, as they expect near-term catalysts to drive the stocks higher.
Published:
These are the top analyst upgrades, downgrades and initiations from Wall Street firms for Friday, June 27, 2014. They include Alcoa, Cigna, Intel, Molina Healthcare, Teva Pharmaceutical and...
Published:
Teva Pharmaceutical is finding a bit of a sell-the-news reaction to its first-quarter earnings report. The company said revenues rose 2% from a year ago and net income rose by 8%.
Published:
The specialty pharmaceutical sector is exploding with news of takeovers, exchanges and possible mergers. Here are some of the top stocks started with a rating of Buy at Jefferies.
Published:
These are the top analyst upgrades, downgrades and initiations for Tuesday, April 22, 2014. They include AMD, ARM Holdings, Barrick Gold, Netflix, Teva Pharmaceutical and Valero Energy.
Published:
Teva Pharmaceutical shares reached a new multiyear high Monday after the U.S. Supreme Court agreed to hear its appeal to revive a patent on its top-selling multiple-sclerosis drug.
Published:
These are the top analyst upgrades, downgrades and initiations seen from Wall Street research firms on March 19, 2014. They include Compugen, Enterprise Products Partners, Juniper Networks, Suncor...
Published:
Two analyst upgrades on Friday, a new CEO and a 33% increase in its stock price since November may be confirmation that Teva Pharmaceutical Industries is finally rebounding. Analysts think the stock...
Published:
These are the top analyst upgrades, downgrades and initiations seen from Wall Street research firms on Friday, March 14, 2014. They include Alcoa, BP, NetApp, Plug Power and Teva Pharmaceutical.
Published:
The chief strategist at Piper Jaffray released his report for March. It details how the second and third quarters typically behave in the mid-term years after a solid first quarter. Here are the top...
Published:
These are the top analyst upgrades, downgrades and initiations seen from Wall Street research firms on Friday, March 7, 2014. They include Nokia, Safeway, Sirius XM, Skull Candy and Teva...
Published:
Most Wall Street firms run model portfolios for their institutional and retail clients. Here are stocks that recently were added to the Piper Jaffray Model Portfolio.
Published:
Teva Pharmaceutical Industries is out with its fourth-quarter earnings report, and it looks as though the bad trends may be more and more in the past.
Published: